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Abstract
AIM: To understand the interaction of human IQGAP1 
and CDC42, especially the effects of phosphorylation 
and a cancer-associated mutation.
METHODS: Recombinant CDC42 and a novel C-termi-
nal fragment of IQGAP1 were expressed in, and puri-
fied from, Escherichia coli . Site directed mutagenesis 
was used to create coding sequences for three phos-
phomimicking variants (S1441E, S1443D and S1441E/
S1443D) and to recapitulate a cancer-associated mu-
tation (M1231I). These variant proteins were also ex-
pressed and purified. Protein-protein crosslinking using 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide was 
used to investigate interactions between the C-terminal 
fragment and CDC42. These interactions were quanti-
fied using surface plasmon resonance measurements. 
Molecular modelling was employed to make predictions 
about changes to the structure and flexibility of the 
protein which occur in the cancer-associated variant.
RESULTS: The novel, C-terminal region of human IQGAP1 
(residues 877-1558) is soluble following expression and 
purification. It is also capable of binding to CDC42, as 
judged by crosslinking experiments. Interaction appears 
to be strongest in the presence of added GTP. The 
three phosphomimicking mutants had different affini-
ties for CDC42. S1441E had an approximately 200-fold 
reduction in affinity compared to wild type. This was 
caused largely by a dramatic reduction in the associa-
tion rate constant. In contrast, both S1443D and the 
double variant S1441E/S1443D had similar affinities to 
the wild type. The cancer-associated variant, M1231I, 
also had a similar affinity to wild type. However, in 
the case of this variant, both the association and dis-
sociation rate constants were reduced approximately 
10-fold. Molecular modelling of the M1231I variant, 
based on the published crystal structure of part of the 
C-terminal region, revealed no gross structural changes 
compared to wild type (root mean square deviation of 
0.564 Å over 5556 equivalent atoms). However, pre-
dictions of the flexibility of the polypeptide backbone 
suggested that some regions of the variant protein had 
greatly increased rigidity compared to wild type. One 
such region is a loop linking the proposed CDC42 bind-
ing site with the helix containing the altered residue. It 
is suggested that this increase in rigidity is responsible 
for the observed changes in association and dissocia-
tion rate constants.
CONCLUSION: The consequences of introducing nega-
tive charge at Ser-1441 or Ser-1443 in IQGAP1 are dif-
ferent. The cancer-associated variant M1231I exerts its 
effects partly by rigidifying the protein.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
The IQGAP family of  proteins function at the interface 
between cellular signalling and the cytoskeleton[1-3]. They 
receive information from a variety of  signalling molecules, 
including kinases, small GTPases, growth factor recep-
tors and calcium sensors[4-21]. This information is relayed 
directly to the actin cytoskeleton through interaction with 
filamentous actin (F-actin) which promotes filament bun-
dling and caps the “barbed ends” of  the filaments[22-25]. 
There are also indirect influences on the actin cytoskele-
ton mediated through the Wiskott-Aldrich Syndrome Pro-
tein (WASP) family[24,26] and with microtubules mediated 
via cytoplasmic linker protein 170 (CLIP-170) and adeno-
matous polyposis coli (APC) protein[27,28]. The IQGAP 
proteins are named after two key regions within them-the 
calmodulin binding IQ-motifs and GTPase activating pro-
tein (GAP) related domain (GRD). Although the GRD 
does bind the small GTPases CDC42 and Rac1[4], it does 
not function as the GTPase activator. Indeed, the available 
evidence suggests that it inhibits the catalytic activity of  
small GTPases[4,7]. This is consistent with sequence data 
and structural predictions. GAPs function by inserting 
an “arginine finger” into the active site of  small GTPases 
which acts as a proton donor in the enzymatic mechanism 
of  GTP hydrolysis[29-31]. IQGAPs lack this arginine residue 
and are thus not expected to be able to enhance the rate 
of  GTP hydrolysis.
Humans have three IQGAP isoforms, IQGAP1, IQGAP2 
and IQGAP3 with the first of  these being the best 
characterised[32]. Like family members from other spe-
cies they share a common domain organisation in which 
the actin-binding calponin homology domain (CHD) is 
at the N-terminus of  the protein, the IQ-motifs are ap-
proximately in the middle of  the primary sequence and 
the GRD is towards the C-terminus (Figure 1). There is 
no complete, three-dimensional structure of  an IQGAP 
available, but it is assumed that the various domains fold in 
such a way to enable communication between them. It is 
also anticipated that there is considerable capacity for con-
formational change in the molecule in order to receive, inte-
grate, interpret and output signals. The structures of  some 
isolated domains have been determined. The structure of  
the CHD from human IQGAP1 has been solved by NMR 
spectroscopy and an x-ray structure of  part of  the GRD is 
also available[33,34]. Molecular modelling has predicted largely 
α-helical structures for the IQ-motifs[16,35].
In vitro biochemical studies on IQGAPs have tended 
to rely on fragments of  the protein which are amenable 
to recombinant expression and purification in bacterial 
systems. CDC42 and Rac1 interaction with the GRD is 
promoted by the presence of  GTP[4]. Phosphorylation of  
human IQGAP1 at Ser-1443, however, promotes interac-
tion with CDC42 in the absence of  nucleotide[36]. This 
phosphorylation, along with one at Ser-1441, promotes 
outgrowth of  neurites[37].
Given the protein’s involvement in the transduction 
of  information from signalling pathways to the cytoskel-
eton, it is not surprising that it has been implicated in 
various types of  cancer[38,39]. However, only one cancer-
associated mutation in the coding sequence of  the Iqgap1 
gene has been identified; this mutation results in the 
amino acid change M1231I[40]. It is not clear how this 
change affects the function of  IQGAP1, although it does 
lie in the GRD prompting the hypothesis that it interferes 
with GTPase binding. However, this has not been tested 
experimentally.
Here, we identified a novel, biochemically amenable 
fragment from the C-terminal region of  human IQGAP1 
and confirmed that it is active, as judged by it ability to 
bind CDC42 in a crosslinking experiment. We then de-
scribe a detailed, quantitative investigation into the affin-
ity of  this interaction in the absence of  added GTP. To 
probe the molecular consequences of  phosphorylation in 
this region we used “phosphomicking” variants in which 
serine residues are replaced with negatively charged 
ones. We also recapitulated the cancer-associated variant 
M1231I in order to investigate its binding properties and 
carried out molecular modelling studies to provide fur-
ther understanding the consequences of  this alteration.
MATERIALS AND METHODS
Expression and purification of wild type and variant 
human IQGAP C-terminal region
The sequence encoding amino acids 877-1558 in human 
IQGAP1 was amplified by polymerase chain reaction 
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Figure 1  A schematic representation of human IQGAP1. The domains are 
shown on a linear representation of the protein sequence. The folded protein 
is unlikely to be arranged in a linear fashion and it is possible that some of 
these domains contact each other. CHD�� Calponin homology domain �residues     
44-159); WW�� WW domain �679-712); IQ�� IQ-motifs containing region �745-864); 
GRD�� GAP-related domain �1004-1237); RGC�� Ras-GAP C-terminal domain 
(1563-1657). The definitions of the domain boundaries are those of Briggs and 
Sacks[2].
(PCR) using the Kazusa cDNA clone KIAA0051[41] as a 
template. The sequence was inserted into the pET-46 Ek/
LIC (Merck, Nottingham, United Kingdom) by ligation 
independent cloning according to the manufacturer’s in-
structions. Insertion into this vector introduces sequence 
encoding the amino acids MAHHHHHHVDDDDK at 
the 5′-end of  the coding sequence. The complete coding 
sequence was verified (MWG Biotech, Ebersburg, Ger-
many). The plasmid was transformed in to competent 
Escherichia coli (E. coli) HMS174(DE3). Colonies result-
ing from these transformations were picked and grown, 
shaking at 37 ℃, overnight in 5 mL of  Luria-Bertani me-
dium supplemented with 100 μg/mL of  ampicillin. This 
overnight culture was diluted in to 1 L of  Luria- Bertani 
medium supplemented with 100 μg/mL of  ampicillin and 
grown, shaking at 37 ℃ until the cell density, as estimated 
by the A600 nm reached 0.6 to 1.0 (typically 3-4 h). The cul-
ture was the induced by the addition of  1 mmol/L IPTG 
and grown for a further 3 h. Cells were harvested by cen-
trifugation (4200 g for 15 min), resuspended in 20 mL of  
buffer R [50 mmol/L Hepes-OH, pH 7.5, 150 mmol/L 
sodium chloride, 10 %(v/v) glycerol] and stored, frozen at 
-80 ℃ until required.
These cell suspensions were thawed and then disrupt-
ed by sonication (three 30 s pulses of  100 W, with 30-60 s 
gaps in between to allow cooling of  the cells). Cell debris 
was removed by centrifugation (20  000 g for 15 min) and 
the supernatant applied to a 1 mL nickel-agarose column 
(His-Select, Sigma, Poole, United Kingdom) which had 
been previously equilibrated in buffer A [50 mmol/L 
Hepes-OH, pH 7.5, 500 mmol/L sodium chloride, 10 
%(v/v) glycerol]. The cell extract was allowed to pass 
through the column by gravity flow and the column was 
washed with 20 mL of  buffer A. Protein was eluted with 
three 2 mL washes of  buffer B (buffer A supplemented 
with 250 mmol/L imidazole). Protein containing fractions 
were identified by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and dialysed overnight 
at 4 ℃ against buffer D (buffer R supplemented with 2 
mmol/L dithiothreitol). The protein concentration was 
determined by the method of  Bradford[42], using bovine 
serum albumin as a standard. Aliquots (50-100 μL) of  the 
protein were stored frozen at -80 ℃.
Mutations were introduced in to the coding sequence 
using the “QuikChange” protocol[43] and verified by 
DNA sequencing. Each variant protein was expressed in, 
and purified from, E. coli using essentially the same pro-
cedure as outlined above for the wild type.
Expression and purification of human CDC42
The complete coding sequence of  human CDC42 was 
amplified by PCR using IMAGE clone 3626647[44] as a 
template and inserted into pET-46 Ek/LIC. The DNA 
sequence of  the insert was verified. The expression and 
purification of  the protein was carried out using the same 
protocol as for IQGAP1-CTD.
Crosslinking of CDC42 and IQGAP
GTP bound CDC42 was prepared by incubating a mix-
tures of  6 μmol/L CDC42, 0.9 mmol/L GTP and 0.9 
magnesium chloride on ice for 30 min. Nucleotide-deplet-
ed (ND) CDC42 was prepared by incubating 6 μmol/L 
CDC42 with 5 mmol/L EDTA on ice for 30 min. Pro-
tein-protein crosslinking was carried out using 1-Ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC). Methods 
were based on those previously used for the detection of  
interaction between the atrial myosin essential light chain 
and F-actin[45,46]. Untreated, GTP-loaded or ND CDC42 (3 
μmol/L) was mixed with IQGAP(DR6) (3 μmol/L) and 
incubated for 30 min at 22 ℃. EDC was then added to 
a final concentration of  0.6 mmol/L and the incubation 
continued for a further 60 min. Products were analysed by 
SDS-PAGE.
Surface plasmon resonance
Surface plasmon resonance was measured using a BI-
Acore 3000 instrument (BIAcore, Uppsala, Sweden). 
Prior to analysis all proteins were dialysed into HBS Buf-
fer (BIAcore; 10 mmol/L Hepes, pH 7.4, 150 mmol/L 
NaCl). CDC42 was immobilised onto a CM5 sensor chip 
(BIAcore) using N-hydroxysuccinimide (NHS)/EDC 
chemistry. The surface was activated with a mixture of  
100 mmol/L NHS and 400 mmol/L EDC for 30 min. 
CDC42 (25 μmol/L) was then flowed over the surface for 
two 7 min periods and the surface was then blocked and 
deactivated with 1 M ethanolamine for 30 min. Immo-
bilisation of  CDC42 resulted in a change in the response 
units (RU) of  approximately 1400 RU.
Binding was measured by flowing 0.5 μmol/L to 2.5 
μmol/L IQGAP(DR6) over the surface for 300 s (asso-
ciation phase) followed by buffer for 300 s (dissociation 
phase). In between binding measurements, the surface 
was regenerated by the injection of  sodium hydroxide (5 
mmol/L for 220 s). For each binding measurements con-
trols were carried out in parallel in which the protein was 
flowed over a cell which had been activated with NHS/
EDC and blocked with ethanolamine. To determine the 
response due to interaction between IQGAP(DR6) and 
CDC42, the readings for the controls were subtracted 
from the experimental ones. The association and dissocia-
tion rate constants (ka and kd, respectively) and the dis-
sociation equilibrium constant (KD) were determined by 
non-linear curve fitting of  the data using BIAevaluation 
software.
Molecular modelling
The structure of  human IQGAP1, residues 962-1345 (PDB 
3FAY)[34], was taken as a starting point for molecular mod-
elling studies. This structure file describes one, unbroken 
polypeptide chain. The selenomethionine residues in this 
structure were altered to methionine using PyMol (www.
pymol.org) and the resulting structure energy minimised 
using YASARA[47]. Residue 1231 in this minimised struc-
ture was altered to isoleucine, and the mutated structure 
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re-minimised using YASARA. Polypeptide flexibility was 
estimated by generating 500 conformers in the momen-
tum motion type mode of  FIRST/FRODAN with an 
energy cut off  of  -1 kcal/mol[48,49].
RESULTS
Identification of a biochemically tractable C-terminal 
fragment of human IQGAP1
Previous reports demonstrated that a fragment beginning 
at residue 864 and continuing through to the C-terminus of  
the protein (residue 1657) can be expressed in, and purified 
from, E. coli, albeit at relatively low levels[4]. We noted that 
the structure of  the Ras-GAP C-terminal domain (RGD), 
a 112 amino acid residue region at the extreme C-terminus 
of  the protein has been deposited in the Protein Data 
Bank (PDB ID: 1X0H). From this we reasoned that there 
must be a domain boundary in the region of  residue 1545. 
Therefore, a region beginning at residue 877 and finishing 
at 1558 was expressed. This fragment, which we named 
IQGAP1(DR6), can be purified with good yield, typi-
cally 1-2 mg per litre of  E. coli culture (Figure 2A). Similar 
purities and yields were achieved with the various variant 
proteins also described in this work (data not shown). Full 
length, recombinant, human CDC42 could also be purified 
in good yield (Figure 2B).
Interactions between CDC42 and IQGAP1(DR6)
Recombinant, human CDC42 was shown to interact with 
the C-terminal domain fragment. The two proteins could 
be cross-linked using the reagent EDC which is specific 
to carboxylate and amino groups (Figure 3). This demon-
strates that the recombinant C-terminal fragment is likely 
to be folded and is functional. The amount of  crosslinked 
product was greatest in the presence of  GTP (Figure 3).
Effects of phosphomimicking mutations
To investigate the effects of  phosphorylation at serines 
1441 and 1443, the phosphomimic variants S1441E, 
S1443D and S1441E/S1443D were constructed. These 
amino acid changes insert negative charges into the struc-
ture at the sites which can be phosphorylated. Similar mu-
tants have been shown to recapitulate the effects of  phos-
phorylation in an in vivo cell model[37]. Since it has been 
hypothesised that phosphorylation increases the affinity 
for CDC42 in the absence of  GTP[36], this interaction was 
investigated by surface plasmon resonance. Interaction 
between the wild type and immobilised CDC42 could be 
detected by surface plasmon resonance in the absence of  
added GTP (Figure 4). Fitting of  these data resulted in 
rate constants for the association and dissociation phases 
of  the reactions (ka and kd) and, consequently, a value for 
the dissociation constant (KD) (Table 1). It was noted that 
these fits were not perfect with some non-random residu-
als (not shown). This may indicate that there is heteroge-
neity in the preparations and/or that the binding event is 
more complex. However, for the purposes of  compari-
son, the simple bimolecular interaction model was used 
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Figure 2  Proteins used in this study. The recombinant expression and pu-
rification of (A) IQGAP1(DR6) and (B) CDC42 monitored by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). In both (A) and (B), U, 
extract from cells prior to induction; I, extract from cells 2-3 h after induction; S, 
soluble material remaining after sonication; F, material which flowed through the 
column without binding; W, material removed in the washing steps; E, elutions; 
M, molecular mass markers (with their masses shown to the side of the gel in 
kDa). In the case of CDC42, F and W were combined into a single sample.
B
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Figure 3  Interaction between IQGAP1 and CDC42. An interaction be-
tween IQGAP1�DR6) and CDC42 can be detected by EDC crosslinking in 
the presence of GTP. In the absence of EDC (lanes headed -EDC), a mixture 
of IQGAP(DR6) and CDC42 (lane C) behaves the same on SDS-PAGE as 
IQGAP1�DR6) and nucleotide-depleted CDC42 �lane ND) and as IQGAP1�DR6) 
and GTP-loaded CDC42 �lane GTP). In the presence of the crosslinker �lanes 
headed +EDC), crosslinking was not observed between IQGAP(DR6) and 
CDC42 (C) or IQGAP(DR6) and nucleotide-depleted CDC42 (ND). However 
an additional band, corresponding to approximately the combined molecular 
masses of IQGAP�DR6) and CDC42 is seen with GTP-loaded CDC42 �GTP).
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throughout. 
All three phosphomimic variants also bound to CDC42 
in the absence of  additional nucleotide. However, in the 
case of  S1441E, the affinity was reduced by two orders of  
magnitude. This arises mainly because of  a reduction in 
the association rate constant. It should be noted that this 
reduced value (12 l.mol-1.s-1) is very low and, therefore, may 
be subject to greater error than the other values. Interest-
ingly, the double mutant (S1441E/S1443D) binds with a 
similar affinity to the wild type (Table 1).
Effects of the cancer-associated mutation, M1231I
The ability of  the disease-associated variant to interact 
with CDC42 was tested by surface plasmon resonance. 
These experiments suggest that it is able to do so with 
similar affinity to the wild type protein. However, both 
the association and dissociation rate constants are re-
duced compared to wild type (Table 1).
To help understand the biochemistry of  the M1231I 
variant protein, a molecular model was constructed based 
on the crystal structure of  the GRD. This suggested that 
the overall fold is not greatly changed by the substitution 
of  this methionine for isoleucine (rmsd between the wild 
type and variant protein 0.564 Å over 5556 equivalent at-
oms). The residue lies towards the surface of  the protein, 
away from the predicted GTPase binding site. In addition 
to gross structural changes, the functions of  proteins can 
be affected by the flexibility of  the molecule[50]. Com-
putational estimation of  the backbone flexibility of  the 
molecule suggested that the M1231I variation results in 
changes in flexibility at a number of  sites within the pro-
tein (Figure 5A). The site with the greatest loss of  flex-
ibility is a loop (Ser-1212 to Leu-1217) which links the 
α-helix containing residue 1231 with residues predicted 
to play a key role in the CDC42 binding site (Tyr-1192 to 
Arg-1194; Figure 5B). This loss of  flexibility may affect 
the dynamics of  small GTPase interaction.
DISCUSSION
These experiments establish a new fragment from the 
C-terminal region of  human IQGAP1 which is amenable 
to biochemical analysis. The fragment interacts with 
CDC42, and the strength of  interaction is increased in 
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Figure 4  Interaction of IQGAP-CTD and CDC42 can be detected by 
surface plasmon resonance. Typical sensorgrams resulting from flowing 
IQGAP1(DR6) wild type and variants over immobilised CDC42 (for conditions, 
see Materials and Methods). From top to bottom, wild type, S1441E, S1443D, 
S1441E/S1443D, M1231I. Protein concentrations are shown to the right of the 
sensorgrams. 
Table 1  Binding parameters for the interaction of 
IQGAP1(DR6) and CDC42
IQGAP1(DR6) variant k a/l.mol-1.s-1 k d/s-1 K D/μmol/L
Wild type 4900 ± 100 ��.� ± 0.�� × 10��     1.� ± 0.1�
S1441E 12 ± 1   �2.7 ± 0.0�� × 10�� 220 ± 21
S144�D �800 ± 100 �4.7 ± 0.2� × 10��     0.81 ± 0.048
S1441E/S144�D ��00 ± 100 �4.0 ± 0.2� × 10��       1.1 ± 0.08�
�12�1I 1800 ± 100 �1.7 ± 0.2� × 10��   0.90 ± 0.1�
T��ese we�e dete�mined by su�f��e pl�smon �eson�n�e. T��e v�lues ��e 
�epo�ted ± t��ei� st�nd��d e��o�s �s dete�mined by t��e BIAev�lu�tion 
fitting programme (see Materials and Methods). 
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the presence of  GTP. Interestingly, previous work has 
demonstrated, using isothermal titration calorimetry, an 
interaction between a C-terminal fragment of  IQGAP 
(residues 962-1345) and GTP-loaded CDC42, but not 
with CDC42 purified in the absence of  added nucleo-
tides (assumed to be GDP-loaded)[34]. This may indicate 
that the additional residues present in the IQGAP1(DR6) 
fragment are important in CDC42 interaction in the 
absence of  GTP. The phosphomimicking variants sug-
gest that phosphorylation of  the two serine residues has 
different effects. While the S1443D variant has slightly 
increased affinity for CDC42, the affinity of  S1441E is 
decreased and introduction of  a negative charge at both 
sites restores the affinity to essentially wild type levels. 
This suggests that there may be crosstalk between the 
two serines within the C-terminal domain. The results 
from the cancer-associated variant emphasise the impor-
tance of  considering changes in protein flexibility, as well 
as changes to overall structure.
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Background
IQGAP family proteins act as “molecular telephone exchanges” collecting infor-
mation from a variety of cellular signalling pathways, integrating this informa-
tion and passing it on to the cytoskeleton. They are multi-domain proteins and 
biochemical studies have tended to concentrate on elucidating the roles of the 
individual domains. Given their role in organising the cytoskeleton in response 
to cellular signalling, it is not surprising that IQGAPs are implicated in a number 
of diseases, including bacterial infections and cancers.
Research frontiers
Human IQGAP1’s activity can be regulated by phosphorylation at serines 1441 
and 1443. There is also a cancer-associated mutation, M1231I. All these resi-
dues lie in the C-terminal, GTPase-binding region of the protein. The molecular 
consequences of these changes on the affinity of IQGAP1 for CDC42 have not 
been investigated in detail previously.
Innovations and breakthroughs
We demonstrate that phosphomimicking alterations at residues 1441 and 1443 
have different effects on the affinity for CDC42. The M1231I variant has similar 
affinity for wild type, but the association and dissociation rate constants are 
both reduced. Molecular modelling suggests that this variant does not cause 
any significant structural changes to the protein, but that it does reduce mobility 
in a key loop which links the residue 1231 to the putative CDC42 binding site.
Applications
The biochemically amenable, functional fragment of human IQGAP1 which we 
identify will have application in further biochemical studies on this protein. If fur-
ther cancer-associated mutations are discovered in Iqgap1 it will be interesting 
to compare results and see if these also alter the flexibility of the protein.
Terminology
Cancer-associated mutation�� A mutation in the gene sequence encoding a pro-
tein which is associated with a higher risk of cancer. Care should be taken not 
to assume that the mutation causes cancer. CDC42: A small GTPase involved 
in regulating the cytoskeleton in eukaryotic cells; Crosslinking�� A method for de-
tecting interactions between proteins. It is especially useful for capturing short-
lived, transient interactions (which are often found in signalling complexes); 
IQGAP: A family of cytoskeletal scaffolding proteins. Humans have three-
IQGAP1, IQGAP2 and IQGAP3.
Peer review
This manuscript is worthy of publishing because the contents do accord with 
the Journal scopes and the biochemical characterization provides insight to un-
derstand IQGAP/CDC43 interaction. The technique is sound; but the discussion 
is not thorough. 
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